Samantha Young1, Evan Wood1,2, M-J Milloy1,2, Kora DeBeck2,3, Sabina Dobrer2, Ekaterina Nosova2, Thomas Kerr1,2, Kanna Hayashi PhD2,4. 1. a Department of Medicine , University of British Columbia , Vancouver , British Columbia , Canada. 2. b British Columbia Centre on Substance Use, British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital , Vancouver , British Columbia , Canada. 3. c School of Public Policy , Simon Fraser University , Vancouver , British Columbia , Canada. 4. d Faculty of Health Sciences , Simon Fraser University , Burnaby , British Columbia , Canada.
Abstract
BACKGROUND: People who inject drugs (PWID) have high rates of hepatitis C virus (HCV) infection. Little is known about the rates of diagnosis and treatment for HCV among PWID. Therefore, this study aims to characterize the cascade of care in Vancouver, Canada, to improve HCV treatment access and delivery for PWID. METHODS: Data were derived from 3 prospective cohort studies of PWID in Vancouver, Canada, between December 2005 and May 2015. The progression of participants was identified through 5 steps in the cascade of care: (1) chronic HCV; (2) linkage to HCV care; (3) liver disease assessment; (4) initiation of treatment; and (5) completion of treatment. Predictors of undergoing liver disease assessment for HCV treatment were identified using a multivariable extended Cox regression model. RESULTS: Among 1571 participants with chronic HCV, 1359 (86.5%) had ever been linked to care, 1257 (80.0%) had undergone liver disease assessment, 163 (10.4%) had ever started HCV treatment, and 71 (4.5%) had ever completed treatment. In multivariable analyses, human immunodeficiency virus (HIV) seropositivity, use of methadone maintenance therapy, and hospitalization in the past 6 months were independently and positively associated with undergoing liver disease assessment (all P < .001), whereas daily heroin injection was independently and negatively associated with undergoing liver disease assessment (P < .001). CONCLUSIONS: Among this cohort of PWID, few had been started on or completed treatment for HCV. These findings highlight the need to improve the prescribing of HCV treatment among PWID with active substance use.
BACKGROUND:People who inject drugs (PWID) have high rates of hepatitis C virus (HCV) infection. Little is known about the rates of diagnosis and treatment for HCV among PWID. Therefore, this study aims to characterize the cascade of care in Vancouver, Canada, to improve HCV treatment access and delivery for PWID. METHODS: Data were derived from 3 prospective cohort studies of PWID in Vancouver, Canada, between December 2005 and May 2015. The progression of participants was identified through 5 steps in the cascade of care: (1) chronic HCV; (2) linkage to HCV care; (3) liver disease assessment; (4) initiation of treatment; and (5) completion of treatment. Predictors of undergoing liver disease assessment for HCV treatment were identified using a multivariable extended Cox regression model. RESULTS: Among 1571 participants with chronic HCV, 1359 (86.5%) had ever been linked to care, 1257 (80.0%) had undergone liver disease assessment, 163 (10.4%) had ever started HCV treatment, and 71 (4.5%) had ever completed treatment. In multivariable analyses, human immunodeficiency virus (HIV) seropositivity, use of methadone maintenance therapy, and hospitalization in the past 6 months were independently and positively associated with undergoing liver disease assessment (all P < .001), whereas daily heroin injection was independently and negatively associated with undergoing liver disease assessment (P < .001). CONCLUSIONS: Among this cohort of PWID, few had been started on or completed treatment for HCV. These findings highlight the need to improve the prescribing of HCV treatment among PWID with active substance use.
Entities:
Keywords:
Cascade of care; harm reduction; hepatitis C; injection drug use; treatment
Authors: Geert Robaeys; Hans Van Vlierberghe; Catharina Matheï; Marc Van Ranst; Liesbeth Bruckers; Frank Buntinx Journal: Eur J Gastroenterol Hepatol Date: 2006-02 Impact factor: 2.566
Authors: Paul K Nelson; Bradley M Mathers; Benjamin Cowie; Holly Hagan; Don Des Jarlais; Danielle Horyniak; Louisa Degenhardt Journal: Lancet Date: 2011-07-27 Impact factor: 79.321
Authors: Steffanie A Strathdee; M Latka; J Campbell; P T O'Driscoll; E T Golub; F Kapadia; R A Pollini; R S Garfein; D L Thomas; H Hagan Journal: Clin Infect Dis Date: 2005-04-15 Impact factor: 9.079
Authors: Davina Swan; Jean Long; Olivia Carr; Jean Flanagan; Helena Irish; Shay Keating; Michelle Keaveney; John Lambert; P Aiden McCormick; Susan McKiernan; John Moloney; Nicola Perry; Walter Cullen Journal: AIDS Patient Care STDS Date: 2010-12 Impact factor: 5.078
Authors: Natasha K Martin; Peter Vickerman; Jason Grebely; Margaret Hellard; Sharon J Hutchinson; Viviane D Lima; Graham R Foster; John F Dillon; David J Goldberg; Gregory J Dore; Matthew Hickman Journal: Hepatology Date: 2013-08-26 Impact factor: 17.425
Authors: Judith I Tsui; Claire M Miller; John D Scott; Maria A Corcorran; Julia C Dombrowski; Sara N Glick Journal: Drug Alcohol Depend Date: 2018-12-26 Impact factor: 4.492
Authors: Brianna L Norton; Matthew J Akiyama; Linda Agyemang; Moonseong Heo; Irene- Pericot-Valverde; Alain H Litwin Journal: Open Forum Infect Dis Date: 2020-08-26 Impact factor: 3.835